MAP2K7 and melanoma: These data suggest that an additional therapeutic benefit in patients with melanoma could derive from the combination of BRAF and MEK-inhibitors with other immunomodulating agents, such as immune check-points inhibitors, agonists of T-cell co-stimulatory receptors, or chemokine/chemokine receptor inhibitors [90].